Profile data is unavailable for this security.
About the company
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
- Revenue in USD (TTM)0.00
- Net income in USD-127.27m
- Incorporated2017
- Employees103.00
- LocationBiomea Fusion Inc900 Middlefield Road, 4Th FloorREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 980-9099
- Fax+1 (302) 655-5049
- Websitehttps://www.biomeafusion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mersana Therapeutics Inc | 36.86m | -171.67m | 423.37m | 123.00 | -- | 11.32 | -- | 11.49 | -1.50 | -1.50 | 0.3175 | 0.3057 | 0.1315 | -- | 2.46 | 299,634.20 | -61.27 | -61.68 | -84.73 | -81.35 | -- | -- | -465.80 | -622.19 | -- | -- | 0.408 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Replimune Group Inc | 0.00 | -209.96m | 426.65m | 284.00 | -- | 1.01 | -- | -- | -3.16 | -3.16 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -34.66 | -26.12 | -36.63 | -27.31 | -- | -- | -- | -- | -- | -- | 0.1436 | -- | -- | -- | -47.65 | -- | 75.59 | -- |
| Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 428.45m | 285.00 | -- | 1.48 | -- | 185.40 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| ACELYRIN Inc | 0.00 | -381.64m | 430.27m | 130.00 | -- | 0.6486 | -- | -- | -10.84 | -10.84 | 0.00 | 6.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Tscan Therapeutics Inc | 21.05m | -89.22m | 430.59m | 154.00 | -- | 2.71 | -- | 20.46 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Entrada Therapeutics Inc | 129.01m | -6.69m | 442.19m | 159.00 | -- | 1.82 | -- | 3.43 | -0.2543 | -0.2543 | 3.86 | 7.25 | 0.3578 | -- | -- | 811,402.50 | -1.85 | -- | -2.47 | -- | -- | -- | -5.18 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 170.28m | -225.25m | 443.58m | 709.00 | -- | 1.42 | -- | 2.61 | -1.56 | -1.56 | 1.18 | 2.13 | 0.2244 | 5.23 | 4.36 | 240,163.60 | -29.69 | -19.69 | -34.13 | -22.06 | 55.63 | 67.18 | -132.32 | -122.27 | 4.50 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 444.71m | 103.00 | -- | -- | -- | -- | -3.57 | -3.57 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -43.29 | -- | -- | -- |
| Annexon Inc | 0.00 | -134.24m | 444.77m | 71.00 | -- | 1.53 | -- | -- | -1.78 | -1.78 | 0.00 | 3.20 | 0.00 | -- | -- | 0.00 | -46.07 | -44.06 | -49.49 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Cartesian Therapeutics Inc | 26.00m | -219.71m | 455.58m | 38.00 | -- | -- | -- | 17.52 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Theravance Biopharma Inc | 57.42m | -55.19m | 459.38m | 99.00 | -- | 2.14 | -- | 8.00 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| PepGen Inc | 0.00 | -78.63m | 459.94m | 64.00 | -- | 3.12 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Fate Therapeutics Inc | 63.53m | -160.93m | 462.10m | 181.00 | -- | 1.09 | -- | 7.27 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| C4 Therapeutics Inc | 20.76m | -132.49m | 462.37m | 145.00 | -- | 1.66 | -- | 22.28 | -2.67 | -2.67 | 0.4181 | 4.07 | 0.0514 | -- | 3.13 | 143,144.80 | -32.82 | -25.91 | -36.80 | -29.45 | -- | -- | -638.34 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Editas Medicine Inc | 78.12m | -153.22m | 466.27m | 265.00 | -- | 1.33 | -- | 5.97 | -2.06 | -2.06 | 1.03 | 4.27 | 0.1542 | -- | 10.19 | 294,803.80 | -30.24 | -29.85 | -34.43 | -33.19 | -- | -- | -196.13 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Data as of May 03 2024. Currency figures normalised to Biomea Fusion Inc's reporting currency: US Dollar USD
69.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.36m | 15.00% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.49m | 12.56% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 3.57m | 10.00% |
| Laurion Capital Management LPas of 31 Dec 2023 | 2.74m | 7.66% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 2.11m | 5.91% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.71m | 4.78% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 1.71m | 4.78% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.29m | 3.62% |
| Driehaus Capital Management LLCas of 31 Dec 2023 | 1.18m | 3.31% |
| Aisling Capital Management LPas of 31 Dec 2023 | 798.76k | 2.24% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
